Silverarc Capital Management LLC Purchases 6,519 Shares of Disc Medicine, Inc. (NASDAQ:IRON)

Silverarc Capital Management LLC boosted its position in shares of Disc Medicine, Inc. (NASDAQ:IRON - Free Report) by 6.3% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 110,381 shares of the company's stock after acquiring an additional 6,519 shares during the period. Disc Medicine accounts for 1.5% of Silverarc Capital Management LLC's investment portfolio, making the stock its 23rd biggest holding. Silverarc Capital Management LLC owned approximately 0.37% of Disc Medicine worth $6,998,000 at the end of the most recent reporting period.

A number of other hedge funds also recently bought and sold shares of the company. FMR LLC lifted its position in shares of Disc Medicine by 358.7% during the 4th quarter. FMR LLC now owns 1,866,248 shares of the company's stock worth $118,320,000 after purchasing an additional 1,459,434 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Disc Medicine in the fourth quarter valued at approximately $5,579,000. Renaissance Technologies LLC acquired a new stake in shares of Disc Medicine in the fourth quarter worth $5,479,000. Dimensional Fund Advisors LP raised its stake in Disc Medicine by 160.8% during the 4th quarter. Dimensional Fund Advisors LP now owns 139,720 shares of the company's stock valued at $8,856,000 after purchasing an additional 86,154 shares during the last quarter. Finally, Geode Capital Management LLC raised its stake in Disc Medicine by 17.6% during the 3rd quarter. Geode Capital Management LLC now owns 474,719 shares of the company's stock valued at $23,333,000 after purchasing an additional 70,983 shares during the last quarter. 83.70% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on IRON shares. Scotiabank upped their price objective on shares of Disc Medicine from $73.00 to $75.00 and gave the company a "sector outperform" rating in a research report on Monday, March 3rd. Cantor Fitzgerald raised their price objective on Disc Medicine from $99.00 to $132.00 and gave the stock an "overweight" rating in a research report on Tuesday, March 18th. TD Cowen started coverage on Disc Medicine in a research report on Thursday, February 27th. They set a "buy" rating on the stock. Stifel Nicolaus raised their target price on Disc Medicine from $90.00 to $94.00 and gave the stock a "buy" rating in a research report on Friday, January 24th. Finally, HC Wainwright reiterated a "buy" rating and set a $118.00 price target on shares of Disc Medicine in a research note on Tuesday, January 21st. Ten investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, Disc Medicine has a consensus rating of "Buy" and an average price target of $93.80.

Disc Medicine Price Performance

Shares of IRON traded down $0.75 on Friday, hitting $45.42. The company's stock had a trading volume of 273,679 shares, compared to its average volume of 345,429. The company has a 50 day moving average price of $48.55 and a 200 day moving average price of $55.08. Disc Medicine, Inc. has a fifty-two week low of $27.39 and a fifty-two week high of $68.73. The company has a market capitalization of $1.57 billion, a PE ratio of -11.41 and a beta of 0.77.

Disc Medicine (NASDAQ:IRON - Get Free Report) last announced its earnings results on Thursday, February 27th. The company reported ($0.98) earnings per share for the quarter, beating analysts' consensus estimates of ($1.06) by $0.08. On average, equities analysts forecast that Disc Medicine, Inc. will post -4.07 EPS for the current year.

Insider Buying and Selling

In other news, insider Pamela Stephenson sold 3,137 shares of the firm's stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $54.58, for a total value of $171,217.46. Following the transaction, the insider now owns 69,529 shares of the company's stock, valued at approximately $3,794,892.82. This trade represents a 4.32 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO John D. Quisel sold 5,574 shares of the business's stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $54.58, for a total transaction of $304,228.92. Following the sale, the chief executive officer now directly owns 154,828 shares of the company's stock, valued at approximately $8,450,512.24. This trade represents a 3.48 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 361,690 shares of company stock worth $19,648,094 in the last quarter. Insiders own 4.24% of the company's stock.

About Disc Medicine

Disc Medicine, Inc, together with its subsidiaries, a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of novel treatments for patients suffering from serious hematologic diseases in the United States. The company has assembled a portfolio of clinical and preclinical product candidates that aim to modify fundamental biological pathways associated with the formation and function of red blood cells, primarily heme biosynthesis and iron homeostasis.